Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma
Background: Fas ligand (Fas-L), which is expressed by melanoma cells, can be cleaved from cell membranes and become soluble (soluble Fas-L, sFas-L). No previous study examined sFas-L levels in patients affected with all clinical stages of melanoma. Objective: To investigate if sFas-L can be consider...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2002-01, Vol.205 (2), p.111-115 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 115 |
|---|---|
| container_issue | 2 |
| container_start_page | 111 |
| container_title | Dermatology (Basel) |
| container_volume | 205 |
| creator | Melzani, Giulia Bugari, Giovanna Parrinello, Giovanni Mori, Giovanni Manganoni, Ausilia Maria De Panfilis, Giuseppe |
| description | Background: Fas ligand (Fas-L), which is expressed by melanoma cells, can be cleaved from cell membranes and become soluble (soluble Fas-L, sFas-L). No previous study examined sFas-L levels in patients affected with all clinical stages of melanoma. Objective: To investigate if sFas-L can be considered a serological marker for melanoma. Methods: Serological sFas-L values in 114 patients with melanoma and 25 controls were measured by using ELISA. Results: sFas-L values in patients were not significantly higher than in controls. They were not significantly different, moreover, when patient groups belonging to different clinical stages were compared with the control group. Two patients affected with distant metastases had the highest sFas-L values. Conclusion: sFas-L cannot be considered, within the limits of this study, as a serological marker for the detection of melanoma. Further studies are needed to evaluate whether sFas-L can be used as a marker for disease progression and/or prediction of therapy outcome. |
| doi_str_mv | 10.1159/000063894 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_journals_275091143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72066704</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-9a6747f642cdcb12b18cc98bd2a980a05f15fef4950ef7eedc6b4800bddbd0413</originalsourceid><addsrcrecordid>eNpt0EtLAzEQB_Agiu-DZ0GCoOBhNa_dTY6i9QEtgtXzMptHWd1uatIV_PZGWyuIc8lAfswMf4QOKDmnNFcXJFXBpRJraJsKRjMlOVtPPaEyk0WRb6GdGF-SYrJUm2iLMkYlY3wbDQbv0PYwb3yHvcNj3_Z1a_ENRDxsJtAZnDrAYxt86yeNhhaPILzagJ0PeGRb6PwU9tCGgzba_eW7i55vBk9Xd9nw4fb-6nKYaS7zeaagKEXpCsG00TVlNZVaK1kbBkoSILmjubNOqJxYV1prdFELSUhtTG2IoHwXnS7mzoJ_622cV9MmatumK6zvY1UyUhQlEQke_4Evvg9duq1iZU4UpYIndLZAOvgYg3XVLDRTCB8VJdVXsNUq2GSPlgP7emrNr1wmmcDJEkBMKbkAnW7ir-OKSU5JcocL9wphYsMK_Kw5_vf3-nH0DaqZcfwTcRSSgw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>275091143</pqid></control><display><type>article</type><title>Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Melzani, Giulia ; Bugari, Giovanna ; Parrinello, Giovanni ; Mori, Giovanni ; Manganoni, Ausilia Maria ; De Panfilis, Giuseppe</creator><creatorcontrib>Melzani, Giulia ; Bugari, Giovanna ; Parrinello, Giovanni ; Mori, Giovanni ; Manganoni, Ausilia Maria ; De Panfilis, Giuseppe</creatorcontrib><description>Background: Fas ligand (Fas-L), which is expressed by melanoma cells, can be cleaved from cell membranes and become soluble (soluble Fas-L, sFas-L). No previous study examined sFas-L levels in patients affected with all clinical stages of melanoma. Objective: To investigate if sFas-L can be considered a serological marker for melanoma. Methods: Serological sFas-L values in 114 patients with melanoma and 25 controls were measured by using ELISA. Results: sFas-L values in patients were not significantly higher than in controls. They were not significantly different, moreover, when patient groups belonging to different clinical stages were compared with the control group. Two patients affected with distant metastases had the highest sFas-L values. Conclusion: sFas-L cannot be considered, within the limits of this study, as a serological marker for the detection of melanoma. Further studies are needed to evaluate whether sFas-L can be used as a marker for disease progression and/or prediction of therapy outcome.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000063894</identifier><identifier>PMID: 12218223</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm - blood ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Child ; Clinical and Laboratory Investigations ; Dermatology ; Enzyme-Linked Immunosorbent Assay ; Fas Ligand Protein ; fas Receptor - blood ; Female ; Humans ; Male ; Medical sciences ; Melanoma - blood ; Melanoma - diagnosis ; Membrane Glycoproteins - blood ; Middle Aged ; Skin Neoplasms - blood ; Skin Neoplasms - diagnosis ; Tumors of the skin and soft tissue. Premalignant lesions</subject><ispartof>Dermatology (Basel), 2002-01, Vol.205 (2), p.111-115</ispartof><rights>2002 S. Karger AG, Basel</rights><rights>2003 INIST-CNRS</rights><rights>Copyright 2002 S. Karger AG, Basel</rights><rights>Copyright (c) 2002 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-9a6747f642cdcb12b18cc98bd2a980a05f15fef4950ef7eedc6b4800bddbd0413</citedby><cites>FETCH-LOGICAL-c385t-9a6747f642cdcb12b18cc98bd2a980a05f15fef4950ef7eedc6b4800bddbd0413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13928310$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12218223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Melzani, Giulia</creatorcontrib><creatorcontrib>Bugari, Giovanna</creatorcontrib><creatorcontrib>Parrinello, Giovanni</creatorcontrib><creatorcontrib>Mori, Giovanni</creatorcontrib><creatorcontrib>Manganoni, Ausilia Maria</creatorcontrib><creatorcontrib>De Panfilis, Giuseppe</creatorcontrib><title>Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Background: Fas ligand (Fas-L), which is expressed by melanoma cells, can be cleaved from cell membranes and become soluble (soluble Fas-L, sFas-L). No previous study examined sFas-L levels in patients affected with all clinical stages of melanoma. Objective: To investigate if sFas-L can be considered a serological marker for melanoma. Methods: Serological sFas-L values in 114 patients with melanoma and 25 controls were measured by using ELISA. Results: sFas-L values in patients were not significantly higher than in controls. They were not significantly different, moreover, when patient groups belonging to different clinical stages were compared with the control group. Two patients affected with distant metastases had the highest sFas-L values. Conclusion: sFas-L cannot be considered, within the limits of this study, as a serological marker for the detection of melanoma. Further studies are needed to evaluate whether sFas-L can be used as a marker for disease progression and/or prediction of therapy outcome.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Neoplasm - blood</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Child</subject><subject>Clinical and Laboratory Investigations</subject><subject>Dermatology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Fas Ligand Protein</subject><subject>fas Receptor - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Melanoma - blood</subject><subject>Melanoma - diagnosis</subject><subject>Membrane Glycoproteins - blood</subject><subject>Middle Aged</subject><subject>Skin Neoplasms - blood</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0EtLAzEQB_Agiu-DZ0GCoOBhNa_dTY6i9QEtgtXzMptHWd1uatIV_PZGWyuIc8lAfswMf4QOKDmnNFcXJFXBpRJraJsKRjMlOVtPPaEyk0WRb6GdGF-SYrJUm2iLMkYlY3wbDQbv0PYwb3yHvcNj3_Z1a_ENRDxsJtAZnDrAYxt86yeNhhaPILzagJ0PeGRb6PwU9tCGgzba_eW7i55vBk9Xd9nw4fb-6nKYaS7zeaagKEXpCsG00TVlNZVaK1kbBkoSILmjubNOqJxYV1prdFELSUhtTG2IoHwXnS7mzoJ_622cV9MmatumK6zvY1UyUhQlEQke_4Evvg9duq1iZU4UpYIndLZAOvgYg3XVLDRTCB8VJdVXsNUq2GSPlgP7emrNr1wmmcDJEkBMKbkAnW7ir-OKSU5JcocL9wphYsMK_Kw5_vf3-nH0DaqZcfwTcRSSgw</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Melzani, Giulia</creator><creator>Bugari, Giovanna</creator><creator>Parrinello, Giovanni</creator><creator>Mori, Giovanni</creator><creator>Manganoni, Ausilia Maria</creator><creator>De Panfilis, Giuseppe</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20020101</creationdate><title>Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma</title><author>Melzani, Giulia ; Bugari, Giovanna ; Parrinello, Giovanni ; Mori, Giovanni ; Manganoni, Ausilia Maria ; De Panfilis, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-9a6747f642cdcb12b18cc98bd2a980a05f15fef4950ef7eedc6b4800bddbd0413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Neoplasm - blood</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Child</topic><topic>Clinical and Laboratory Investigations</topic><topic>Dermatology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Fas Ligand Protein</topic><topic>fas Receptor - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Melanoma - blood</topic><topic>Melanoma - diagnosis</topic><topic>Membrane Glycoproteins - blood</topic><topic>Middle Aged</topic><topic>Skin Neoplasms - blood</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Melzani, Giulia</creatorcontrib><creatorcontrib>Bugari, Giovanna</creatorcontrib><creatorcontrib>Parrinello, Giovanni</creatorcontrib><creatorcontrib>Mori, Giovanni</creatorcontrib><creatorcontrib>Manganoni, Ausilia Maria</creatorcontrib><creatorcontrib>De Panfilis, Giuseppe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Melzani, Giulia</au><au>Bugari, Giovanna</au><au>Parrinello, Giovanni</au><au>Mori, Giovanni</au><au>Manganoni, Ausilia Maria</au><au>De Panfilis, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>205</volume><issue>2</issue><spage>111</spage><epage>115</epage><pages>111-115</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Background: Fas ligand (Fas-L), which is expressed by melanoma cells, can be cleaved from cell membranes and become soluble (soluble Fas-L, sFas-L). No previous study examined sFas-L levels in patients affected with all clinical stages of melanoma. Objective: To investigate if sFas-L can be considered a serological marker for melanoma. Methods: Serological sFas-L values in 114 patients with melanoma and 25 controls were measured by using ELISA. Results: sFas-L values in patients were not significantly higher than in controls. They were not significantly different, moreover, when patient groups belonging to different clinical stages were compared with the control group. Two patients affected with distant metastases had the highest sFas-L values. Conclusion: sFas-L cannot be considered, within the limits of this study, as a serological marker for the detection of melanoma. Further studies are needed to evaluate whether sFas-L can be used as a marker for disease progression and/or prediction of therapy outcome.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>12218223</pmid><doi>10.1159/000063894</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2002-01, Vol.205 (2), p.111-115 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_proquest_journals_275091143 |
| source | MEDLINE; Karger Journals Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Antigens, Neoplasm - blood Biological and medical sciences Biomarkers, Tumor - blood Child Clinical and Laboratory Investigations Dermatology Enzyme-Linked Immunosorbent Assay Fas Ligand Protein fas Receptor - blood Female Humans Male Medical sciences Melanoma - blood Melanoma - diagnosis Membrane Glycoproteins - blood Middle Aged Skin Neoplasms - blood Skin Neoplasms - diagnosis Tumors of the skin and soft tissue. Premalignant lesions |
| title | Evaluation of Soluble Fas Ligand as a Serological Marker for Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A17%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Soluble%20Fas%20Ligand%20as%20a%20Serological%20Marker%20for%20Melanoma&rft.jtitle=Dermatology%20(Basel)&rft.au=Melzani,%20Giulia&rft.date=2002-01-01&rft.volume=205&rft.issue=2&rft.spage=111&rft.epage=115&rft.pages=111-115&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000063894&rft_dat=%3Cproquest_karge%3E72066704%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=275091143&rft_id=info:pmid/12218223&rfr_iscdi=true |